Shennon Biotechnologies Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$12M
- Investors
-
9
Shennon Biotechnologies General Information
Description
Operator of a proprietary single-cell platform intended to study immune cells at the single-cell level on a massive scale to unlock a key bottleneck in immunotherapy. The company's platform provides the functional profile of immune cells on the single-cell level at the same time, pulling out rare and difficult-to-find targets which enables them to develop more effective immunotherapies for cancer enabling the medical industry to create immunotherapies that are more targeted and more effective.
Contact Information
Website
www.shennonbio.comCorporate Office
- 2325 3rd Street
- Suite 327-328
- San Francisco, CA 94107
- United States
Corporate Office
- 2325 3rd Street
- Suite 327-328
- San Francisco, CA 94107
- United States
Shennon Biotechnologies Timeline
Shennon Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series A) | 14-Sep-2026 | $12M | Completed | Startup | ||
| 2. Early Stage VC | 01-Sep-2024 | Completed | Startup | |||
| 1. Seed Round | 13-Mar-2023 | $13M | $13M | Completed | Startup |
Shennon Biotechnologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed 1 | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Shennon Biotechnologies Comparisons
Industry
Financing
Details
Shennon Biotechnologies Competitors (3)
One of Shennon Biotechnologies’s 3 competitors is Vividion Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vividion Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Kymera Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Lycia Therapeutics | Formerly VC-backed | South San Francisco, CA |
Shennon Biotechnologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Shennon Biotechnologies Patents
Shennon Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025259591-A2 | Engineered immune cells and uses thereof | Pending | 10-Jun-2024 | ||
| WO-2025259591-A3 | Engineered immune cells and uses thereof | Pending | 10-Jun-2024 | ||
| WO-2025235657-A1 | Cellular encapsulation methods for improved single cell sequencing | Pending | 07-May-2024 | ||
| EP-4615951-A2 | Microfluidic devices for high throughput screening of cell-cell interactions | Pending | 07-Nov-2022 | ||
| EP-4615951-A4 | Microfluidic devices for high throughput screening of cell-cell interactions | Pending | 07-Nov-2022 | G01N15/1484 |
Shennon Biotechnologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Shennon Biotechnologies Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Atypical Ventures | Venture Capital | Minority | ||
| Saras Capital (England) | Venture Capital | Minority | ||
| Formulate Ventures | Venture Capital | Minority | ||
| Future Ventures (San Francisco) | Venture Capital | Minority | ||
| NextGen Venture Partners | Venture Capital | Minority |
Shennon Biotechnologies FAQs
-
When was Shennon Biotechnologies founded?
Shennon Biotechnologies was founded in 2021.
-
Where is Shennon Biotechnologies headquartered?
Shennon Biotechnologies is headquartered in San Francisco, CA.
-
What is the size of Shennon Biotechnologies?
Shennon Biotechnologies has 16 total employees.
-
What industry is Shennon Biotechnologies in?
Shennon Biotechnologies’s primary industry is Drug Discovery.
-
Is Shennon Biotechnologies a private or public company?
Shennon Biotechnologies is a Private company.
-
What is Shennon Biotechnologies’s current revenue?
The current revenue for Shennon Biotechnologies is .
-
How much funding has Shennon Biotechnologies raised over time?
Shennon Biotechnologies has raised $25M.
-
Who are Shennon Biotechnologies’s investors?
Atypical Ventures, Saras Capital (England), Formulate Ventures, Future Ventures (San Francisco), and NextGen Venture Partners are 5 of 9 investors who have invested in Shennon Biotechnologies.
-
Who are Shennon Biotechnologies’s competitors?
Vividion Therapeutics, Kymera Therapeutics, and Lycia Therapeutics are competitors of Shennon Biotechnologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
